Evaxion新的AI设计的癌症疫苗通过针对独特的白血病抗原,在AML动物模型中减少了肿瘤。 Evaxion's new AI-designed cancer vaccine shrank tumors in AML animal models by targeting unique leukemia antigens.

Evaxion在2025年ASH年会上提供了EVX-04的临床预科数据,EVX-04是针对急性流质血白血病的一种新的现成癌症疫苗(AML)。 Evaxion presented preclinical data for EVX-04, a new off-the-shelf cancer vaccine targeting acute myeloid leukemia (AML), at the 2025 ASH Annual Meeting. 该公司利用其AI-ImmunologyTM平台,在健康组织中未发现的AML肿瘤中发现了多种非常规反转病毒抗原,因此能够作出准确的免疫反应。 Using its AI-Immunology™ platform, the company identified multiple non-conventional retrovirus antigens in AML tumors not found in healthy tissue, enabling a precise immune response. 疫苗引发了强烈的T细胞活动,减少了动物模型的肿瘤生长,所有16个抗原碎片都显示出免疫活性。 The vaccine triggered strong T-cell activity and reduced tumor growth in animal models, with all 16 antigen fragments showing immune activation. EVX-04是一种 " 一刀切 " 疗法,旨在解决反洗钱措施中未满足的大量需求,特别是针对年长或体弱患者的需求,并可能适用于其他难以治疗的癌症。 Designed as a one-size-fits-all therapy, EVX-04 aims to address the high unmet need in AML, especially for older or frail patients, and may apply to other hard-to-treat cancers.